Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Researchers are working to understand why tumors may be resistant to T-cell immunotherapy, and to identify novel targets for immunotherapy.
Customized treatments demonstrate good response rates for mantle cell lymphoma and chronic lymphocytic leukemia.
Study suggests immune-based cancer therapies might be particularly beneficial for HIV-positive people.
Keytruda improves response rates for hard-to-treat breast cancer, but Tecentriq falls short.
Longer-term follow-up shows improved overall survival with Keytruda or Opdivo.
Treatment depends on how advanced the cancer is when detected and whether it has spread elsewhere in the body.
Patients who take probiotics are less likely to respond immunotherapy.
The new documentary follows the pioneering researcher who work helped created checkpoint inhibitor immunotherapy.
Investigators wanted to see if blinatumomab could increase survival rates free from leukemia and be less toxic than intensive chemotherapy.
90% to 100% of study participants achieved complete or partial responses to treatment.
Space travel and chemotherapy affect the body similarly, and yet only astronauts undergo physical conditioning to help them stay strong.
A $4 million grant funds bench-to-bedside research to enhance immune-boosting power of autologous blood stem cell transplantation.
Checkpoint inhibitor combination led to higher response rates and longer survival than Opdivo alone.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.